BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Lee Pharmaceuticals (LPHM) Announces First Quarter Results


10/19/2005 5:12:41 PM

LOS ANGELES, Feb. 10 /PRNewswire-FirstCall/ -- Lee Pharmaceuticals (BULLETIN BOARD: LPHM) reported results for the first quarter ended December 31, 2004. Included in the Company's reported net profit of $85,000 for the three months ended December 31, 2004 was a gain from the sale of a product line for $750,000 cash. The $750,000 gain is included in other income. The net profit of $85,000, or 2 cents per share, is compared to the net profit of $12,000 for the three months ended December 31, 2003.

Gross revenues for the three months ended December 31, 2004 were $2,339,000, a decrease of approximately $487,000, or 17% from the comparable three months ended December 31, 2003. The Company reported decreased volume in several product categories including over the counter items. The decrease in gross revenues was partially offset by an increase in the Lee(R) Lip-Ex(R) lip balm category.

Net revenues decreased approximately $294,000, or 12%, for the three months ended December 31, 2004, as compared to the three months ended December 31, 2003. The change in net revenues was primarily due to the explanations discussed above related to gross revenues. The Company's sales returns decreased approximately $188,000, or 58%, when comparing the three months ended December 31, 2004 and 2003. The Company experienced fewer deductions of their SKUs (stock keeping units) at the retail store level during the three months ended December 31, 2004.

Included in other income, as of the period ended December 31, 2004, were realized gains of approximately $49,000 related to the sale of three products. These realized gains pertain to the recognition of the earned portion of the deferred income of the consulting agreements arising from the sale of these products. Also included is $67,000 arising from a service agreement with an unrelated company and $750,000 arising from the sale of the Nose Better(R) product line. For the quarter ended December 31, 2003, other income consisted of realized gains as described above of $70,000 and $86,000 from the above mentioned consulting and service agreements.

A comparison of the operating results is as follows: Three Months Ended December 31 (000 omitted) 2004 2003 Gross revenues $2,339 $2,826 Net revenues $2,179 $2,473 Total costs and expenses $2,816 $2,426 (Loss) income from operations $(637) $47 Other income (expense) $722 $(35) Net income $85 $12 Per share: Net income $.02 $.00

Lee Pharmaceuticals is engaged in the purchase, manufacture, and marketing of a range of consumer products, including over-the-counter drug items, health and beauty aids, cosmetics and prescription drug products containing controlled substances, and dental/orthodontic products.

Lee Pharmaceuticals

CONTACT: Michael L. Agresti of Lee Pharmaceuticals, +1-626-442-3141,ext. 3219



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->